Investigational drug · Phase 2
AD-3031
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Androgenetic Alopecia.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AD-3031"
First trial start
2026
Apr 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD-3031", any sponsor or status.
Conditions studied
As listed on its trial records.
- Androgenetic Alopecia
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "AD-3031" as an intervention, largest first.
- Assessment of Dutasteride Topical Solution in Male Androgenetic AlopeciaNot yet recruiting
Moogene Medi Co., LtdIndustry
NCT07490327 · 30 participants (planned) · Start Apr 2026 · Primary completion Sep 2026
Drug: AD-303A; AD-3031 · For: Androgenetic Alopecia
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Androgenetic Alopecia
- VDPHL01Phase 34 trials
Veradermics, Inc. · Androgenetic Alopecia, AGA, Male Pattern Baldness
- PP405 0.05%PP405Phase 33 trials
Pelage Pharmaceuticals, Inc. · Androgenetic Alopecia
- DA-001Phase 31 trial
Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- AD-303APhase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
- EPI-001Phase 21 trial
Epibiotech · Androgenetic Alopecia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.